Bermekimab successfully treats Hidradenitis Suppurativa, including pain reduction
XBiotech announced the successful outcome of its multicenter, open label, confirmatory study using bermekimab to treat patients with moderate to severe Hidradenitis Suppurativa. Primary and key secondary endpoints were met in this study with significant, differentiating findings. January 23, 2019